Key Points
The company obliterated the consensus analyst estimates for its second quarter.
Its double-digit growth rates were fueled by sales of exome and genome testing services.
10 stocks we like better than GeneDx ›
The stock of genetic testing company GeneDx Holdings (NASDAQ: WGS) was quite the hot item on the second trading day of the week. After the company published an encouraging second-quarter earnings report, investors piled into its shares to boost them to a more than 8% gain. That looked especially good next to the 0.3% slump of the benchmark S&P 500 index.
Nearly 50% top-line growth in the second quarter
That earnings report, unveiled well before market open that day, revealed that GeneDx booked nearly $103 million in revenue. That was 49% higher year over year and was helped greatly by a 69% improvement in the sales of exome and genome testing services, which hit a total volume of 23,102.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
Better, the company flipped to a bottom-line profit from the year-ago loss. Its non-generally accepted accounting principles, or non-GAAP (adjusted), net income was just under $15 million for the period, comparing most favorably to the over $2 million loss it suffered in the second quarter of 2024. On a per-share basis, GeneDx earned $0.50 in the period.
Both headline figures landed well above the consensus analyst estimates. On average, pundits tracking the company’s stock were expecting only $85 million and some change in revenue and a far lighter adjusted net income figure of $0.12 per share.
Raised hopes
Compounding those solid growth rates, GeneDx raised certain guidance items for the entirety of 2025. The company now believes its revenue will be $400 million to $415 million, significantly higher than the previous estimate of $360 million to $375 million. Much of this will be thanks to exome and genome revenue, now expected to come in at 48% to 52% over the 2024 numbers. Formerly, the projection was 30%.
GeneDx left its adjusted net income growth rate guidance unchanged. The company remains vague about this, predicting only that the metric will be a positive number in each quarter and for the year as a whole.
Should you invest $1,000 in GeneDx right now?
Before you buy stock in GeneDx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GeneDx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $633,452!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,083,392!*
Now, it’s worth noting Stock Advisor’s total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
